Free Trial
→ A weekly dividend fund holding Nvidia and Palantir (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$22.92
+1.7%		$23.40
$19.40
▼
$27.98
$11.26B1.75.75 million shs2.52 million shs
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$14.95
$15.08
$11.08
▼
$18.67
$7.03B0.333,129 shsN/A
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+1.88%+3.17%-2.68%-7.72%+12.67%
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
0.00%0.00%-0.33%+0.34%+44.44%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$22.92
+1.7%		$23.40
$19.40
▼
$27.98
$11.26B1.75.75 million shs2.52 million shs
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$14.95
$15.08
$11.08
▼
$18.67
$7.03B0.333,129 shsN/A
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+1.88%+3.17%-2.68%-7.72%+12.67%
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
0.00%0.00%-0.33%+0.34%+44.44%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.75
Moderate Buy$29.7029.59% Upside
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest ELAN and OPHLF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/30/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
KeyCorp logo
KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/4/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Sell (D+)
9/4/2026
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/20/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D+) ➝ Sell (D)
8/6/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$31.00 ➝ $33.00
8/6/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
KeyCorp logo
KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$29.00 ➝ $30.00
7/31/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Sell (D+)
7/22/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$23.00 ➝ $26.00
7/13/2026
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.43$2.36 per share9.71$13.18 per share1.74
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$3.43B2.05$1.49 per share10.04$11.39 per share1.31
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.41N/A17.771.61-3.96%8.13%3.99%11/6/2026 (Estimated)
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$436.04M$1.0514.24N/AN/A15.02%9.77%7.63%10/28/2026 (Estimated)

Latest ELAN and OPHLF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2026Q3 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.2050N/AN/AN/A$1.21 billionN/A
10/28/2026N/A
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$0.26N/AN/AN/A$726.96 millionN/A
8/5/2026Q2 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.2692$0.34+$0.0708$0.11$1.31 billion$1.37 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.58
2.05
1.10
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
0.08
3.28
2.86

Institutional Ownership

CompanyInstitutional Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
N/A

Insider Ownership

CompanyInsider Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.14%
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.62 million493.93 millionOptionable
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
4,206469.91 millionN/ANot Optionable

Recent News About These Companies

Ono Pharma Advances Pediatric Epilepsy Trial, Bolstering Long-Term Growth Story
October 9 at 12:51 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ono-pharma-advances-pediatric-epilepsy-trial-bolstering-long-term-growth-story?utm_source=marketbeat.com&utm_medium=referral
Biohaven licenses IgG degrader portfolio to Japan’s Ono
October 8 at 6:20 PM  |  seekingalpha.comhttps://seekingalpha.com/news/4651387-biohaven-licenses-igg-degrader-portfolio-to-japans-ono
Ono’s New Pediatric Cancer Trial Signals Steady Pipeline Progress for O.P.H.L.F Investors
October 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/onos-new-pediatric-cancer-trial-signals-steady-pipeline-progress-for-o-p-h-l-f-investors?utm_source=marketbeat.com&utm_medium=referral
Ono Pharmaceutical Co. (OPHLF) Soars 13.9%: Is Further Upside Left in the Stock?
September 24, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2994913/ono-pharmaceutical-co-ophlf-soars-13-9-is-further-upside-left-in-the-stock?cid=cs-stocknewsapi-ft-fundamental_analysis|daily_price_change_5%-2994913
Ono Pharmaceutical Co. (OPHLF) Soars 13.9%: Is Further Upside Left in the Stock?
September 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/ono-pharmaceutical-co-ophlf-soars-110000378.html
Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological Diseases
September 1, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260901390619/en/ono-pharma-enters-into-a-drug-discovery-partnership-with-aitia-in-neurological-diseases/
Ono Pharma’s New Cancer Trial Adds Early-Stage Upside—and Risk—for OPHLF Investors
August 26, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ono-pharmas-new-cancer-trial-adds-early-stage-upside-and-risk-for-ophlf-investors?utm_source=marketbeat.com&utm_medium=referral
Are Investors Undervaluing Ono Pharmaceutical Co. (OPHLF) Right Now?
August 4, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2967495/are-investors-undervaluing-ono-pharmaceutical-co-ophlf-right-now?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_2-2967495
Ono Pharmaceutical Co. (OPHLF) Q1 Earnings and Revenues Top Estimates
July 31, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2965375/ono-pharmaceutical-co-ophlf-q1-earnings-and-revenues-top-estimates?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_4-2965375
Ono Pharma Halts Early Lymphoma Trial, Raising Fresh Questions for Investors
July 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ono-pharma-halts-early-lymphoma-trial-raising-fresh-questions-for-investors?utm_source=marketbeat.com&utm_medium=referral
Earnings Preview: Ono Pharmaceutical Co. (OPHLF) Q1 Earnings Expected to Decline
July 27, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2961096/earnings-preview-ono-pharmaceutical-co-ophlf-q1-earnings-expected-to-decline?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_9-2961096
Strength Seen in Ono Pharmaceutical Co. (OPHLF): Can Its 9.2% Jump Turn into More Strength?
July 27, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2960790/strength-seen-in-ono-pharmaceutical-co-ophlf-can-its-9-2-jump-turn-into-more-strength?cid=cs-stocknewsapi-ft-tale_of_the_tape|daily_price_change_5%-2960790
Ono’s New GIST Study Puts Early‑Stage Oncology Back in Focus for OPHLF Investors
July 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/onos-new-gist-study-puts-earlystage-oncology-back-in-focus-for-ophlf-investors?utm_source=marketbeat.com&utm_medium=referral
Should Value Investors Buy Ono Pharmaceutical Co. (OPHLF) Stock?
July 13, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2952318/should-value-investors-buy-ono-pharmaceutical-co-ophlf-stock?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_2-2952318
Ono Pharmaceutical Co. (OPHLF) moves 10.4% higher: Will this strength last?
July 7, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/ono-pharmaceutical-co-ophlf-moves-104-higher-will-this-strength-last/ar-AA27nMPr
Ono Pharmaceutical Co. (OPHLF) Moves 10.4% Higher: Will This Strength Last?
July 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2949057/ono-pharmaceutical-co-ophlf-moves-10-4-higher-will-this-strength-last?cid=cs-stocknewsapi-ft-tale_of_the_tape|daily_price_change_5%-2949057
Ono Pharma Announces Oral Presentation of New Data from the Phase 2 Clinical Study of ONO-4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting
June 1, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260601543914/en/Ono-Pharma-Announces-Oral-Presentation-of-New-Data-from-the-Phase-2-Clinical-Study-of-ONO-4578-EP4-antagonist-in-Certain-Gastric-Cancers-at-the-ASCO-2026-Annual-Meeting/
Analysts Are Neutral on These Healthcare Stocks: CSL (CMXHF), ONO Pharmaceutical Co (OPHLF)
June 1, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2233396/analysts-are-neutral-on-these-healthcare-stocks-csl-cmxhf-ono-pharmaceutical-co-ophlf/
Ono’s Real-World Tirabrutinib Study in Taiwan Reaches Completion, Setting Up a New Catalyst for OPHLF
May 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/onos-real-world-tirabrutinib-study-in-taiwan-reaches-completion-setting-up-a-new-catalyst-for-ophlf?utm_source=marketbeat.com&utm_medium=referral
Inhibrx cancer drug reportedly drawing interest of Merck and rivals
April 22, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/inhibrx-cancer-drug-reportedly-drawing-interest-of-merck-and-rivals/ar-AA21tfGs

New MarketBeat Followers Over Time

Media Sentiment Over Time

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$22.92 +0.38 (+1.68%)
Closing price 10/9/2026 03:59 PM Eastern
Extended Trading
$22.60 -0.32 (-1.39%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Ono Pharmaceutical stock logo

Ono Pharmaceutical OTCMKTS:OPHLF

$14.95 0.00 (0.00%)
As of 10/9/2026

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas